^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AM-5992

    i
    Other names: AM-5992, AM 5992
    Associations

    News

    Trials
    Company:
    Amgen
    Drug class:
    FLT3 inhibitor, CDK4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    A Breast Cancer Prognostic Model Based on Folic Acid Metabolism-Related Genes to Reveal the Immune Landscape. (PubMed, Horm Metab Res)
    AM-5992 and 5-fluorodeoxyuridine 10mer may be potential BC drugs. This FMR-based model can accurately predict BC prognosis, offering a clinical reference.
    Journal
    |
    IFNG (Interferon, gamma) • BRCA (Breast cancer early onset) • NFKB2 (Nuclear Factor Kappa B Subunit 2) • SERPINA3 (Serpin Family A Member 3)
    |
    AM-5992
    over2years
    FERMT1 Is a Prognostic Marker Involved in Immune Infiltration of Pancreatic Adenocarcinoma Correlating with mA Modification and Necroptosis. (PubMed, Genes (Basel))
    Finally, FERMT1 overexpression may be sensitive to chemotherapy drugs such as Palbociclib, AM-5992 and TAE-226. FERMT1 can serve as a diagnostic and prognostic marker of PAAD, which is connected with immune cell infiltration and the modulation of mA and necroptosis.
    Journal
    |
    FERMT1 (Fermitin Family Member 1)
    |
    FERMT1 expression
    |
    Ibrance (palbociclib) • AM-5992 • NVP-TAE226